79 related articles for article (PubMed ID: 17409406)
1. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation.
Chai J; Lu X; Godfrey V; Fletcher C; Roberts CW; Van Dyke T; Weissman BE
Cancer Res; 2007 Apr; 67(7):3002-9. PubMed ID: 17409406
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.
Kuwahara Y; Mora-Blanco EL; Banine F; Rogers AB; Fletcher C; Sherman LS; Roberts CW; Weissman BE
Int J Cancer; 2013 Jun; 132(12):2767-77. PubMed ID: 23197309
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
DelBove J; Kuwahara Y; Mora-Blanco EL; Godfrey V; Funkhouser WK; Fletcher CD; Van Dyke T; Roberts CW; Weissman BE
Mol Carcinog; 2009 Dec; 48(12):1139-48. PubMed ID: 19676100
[TBL] [Abstract][Full Text] [Related]
4. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
[TBL] [Abstract][Full Text] [Related]
6. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.
Jagani Z; Mora-Blanco EL; Sansam CG; McKenna ES; Wilson B; Chen D; Klekota J; Tamayo P; Nguyen PT; Tolstorukov M; Park PJ; Cho YJ; Hsiao K; Buonamici S; Pomeroy SL; Mesirov JP; Ruffner H; Bouwmeester T; Luchansky SJ; Murtie J; Kelleher JF; Warmuth M; Sellers WR; Roberts CW; Dorsch M
Nat Med; 2010 Dec; 16(12):1429-33. PubMed ID: 21076395
[TBL] [Abstract][Full Text] [Related]
7. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
8. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
Roberts CW; Galusha SA; McMenamin ME; Fletcher CD; Orkin SH
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13796-800. PubMed ID: 11095756
[TBL] [Abstract][Full Text] [Related]
9. Novel germ-line deletion of SNF5/INI1/SMARCB1 gene in neonate presenting with congenital malignant rhabdoid tumor of kidney and brain primitive neuroectodermal tumor.
Kusafuka T; Miao J; Yoneda A; Kuroda S; Fukuzawa M
Genes Chromosomes Cancer; 2004 Jun; 40(2):133-9. PubMed ID: 15101046
[TBL] [Abstract][Full Text] [Related]
10. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.
Ng JM; Martinez D; Marsh ED; Zhang Z; Rappaport E; Santi M; Curran T
Cancer Res; 2015 Nov; 75(21):4629-39. PubMed ID: 26363008
[TBL] [Abstract][Full Text] [Related]
11. Characterization of mammary tumors from Brg1 heterozygous mice.
Bultman SJ; Herschkowitz JI; Godfrey V; Gebuhr TC; Yaniv M; Perou CM; Magnuson T
Oncogene; 2008 Jan; 27(4):460-8. PubMed ID: 17637742
[TBL] [Abstract][Full Text] [Related]
12. The Achilles Heel of Malignant Rhabdoid Tumors.
Huang J; Luo J
Cancer Res; 2019 Jun; 79(11):2808-2809. PubMed ID: 31160308
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
[TBL] [Abstract][Full Text] [Related]
14. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
15. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.
Roberts CW; Leroux MM; Fleming MD; Orkin SH
Cancer Cell; 2002 Nov; 2(5):415-25. PubMed ID: 12450796
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
17. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
Klochendler-Yeivin A; Picarsky E; Yaniv M
Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis.
Guidi CJ; Mudhasani R; Hoover K; Koff A; Leav I; Imbalzano AN; Jones SN
Cancer Res; 2006 Aug; 66(16):8076-82. PubMed ID: 16912184
[TBL] [Abstract][Full Text] [Related]
19. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.
McKenna ES; Sansam CG; Cho YJ; Greulich H; Evans JA; Thom CS; Moreau LA; Biegel JA; Pomeroy SL; Roberts CW
Mol Cell Biol; 2008 Oct; 28(20):6223-33. PubMed ID: 18710953
[TBL] [Abstract][Full Text] [Related]
20. Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability.
Imbalzano AN; Jones SN
Cancer Cell; 2005 Apr; 7(4):294-5. PubMed ID: 15837618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
